Yorvipath
Yorvipath ingredients
| Active ingredient | Strength |
|---|---|
| Palopegteriparatide | 168 ug/.56mL, 420 ug/1.4mL, 294 ug/.98mL |
What Yorvipath is used for
The FDA lists the approved uses on the official label (below). In the EU, palopegteriparatide is approved as Yorvipath for:
Yorvipath is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Yorvipath
- Generic name
- Palopegteriparatide
- Made by
- Ascendis Pharma, Endocrinology, Inc.
- Forms
- Injection, Solution
- Given
- Subcutaneous
- Drug class
- Parathyroid Hormone Analog
- FDA approval
- New drug application (NDA) NDA216490
- On the US market since
- 2024
Official information
- MedlinePlus drug information (search for Palopegteriparatide)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Yorvipath?
Yorvipath (Palopegteriparatide) is a specialist medicine made by Ascendis Pharma, Endocrinology, Inc., approved by the US FDA.
What are the ingredients of Yorvipath?
Yorvipath contains Palopegteriparatide (168 ug/.56mL, 420 ug/1.4mL, 294 ug/.98mL).
Is Yorvipath approved in Europe?
The same active substance is approved in the EU as Yorvipath.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA